Advertisement

Expert Point of View: Paul G. Richardson, MD

Study discussant Paul G. Richardson, MD, the RJ Corman Professor of Medicine at Harvard Medical School and the Jerome Lipper Multiple Myeloma Chair at Dana-Farber Cancer Institute, Boston, commented, “The evolving role of monoclonal antibodies in multiple myeloma has been worth the wait. You can see from the CASTOR study that we are really transforming outcomes with the advent of these molecules.” 

 The ASCO Post

click me